MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30.

Income Overview

Net Income
-$34,441K
EPS
-$0.4
Unit: Thousand (K) dollars

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-09-30
Collaboration revenue
--109,164 791
Research and development
22,526 26,859 26,580 27,228
General and administrative
6,835 7,805 8,408 8,352
Impairment of long-lived assets
6,763 ---
Total operating expenses
36,124 34,664 34,988 35,580
Income (loss) from operations
-36,124 -34,664 74,176 -34,789
Interest income
1,605 2,010 2,422 3,305
Other income
97 113 -38 250
Total other income
1,702 2,123 2,384 3,555
Income (loss) before provision for income taxes
-34,422 -32,541 76,560 -31,234
Income tax expense (benefit)
----8
Net income (loss)
-34,422 -32,541 76,560 -31,226
Unrealized gain (loss) on investments
-19 -222 -19 1,075
Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent
----8
Comprehensive income (loss)
-34,441 -32,763 76,541 -30,159
Earnings per share, basic
-0.4 -0.38 0.89 -0.37
Earnings per share, diluted
-0.4 -0.38 0.89 -0.37
Weighted average number of shares outstanding, basic
86,464,066 86,238,084 86,021,188 84,704,352
Weighted average number of shares outstanding, diluted
86,464,066 86,238,084 86,098,619 84,704,352
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive income (loss)-$34,441K Unrealized gain (loss) oninvestments-$19K Net income (loss)-$34,422K Other income$97K Interest income$1,605K Income (loss) beforeprovision for income taxes-$34,422K Total other income$1,702K Income (loss) fromoperations-$36,124K Total operatingexpenses$36,124K Impairment of long-livedassets$6,763K General andadministrative$6,835K Research and development$22,526K

Century Therapeutics, Inc. (IPSC)

Century Therapeutics, Inc. (IPSC)